Confirm Rx insertable cardiac monitor for primary atrial fibrillation detection in high-risk heart failure patients (Confirm-AF trial).
Mehmet K AktasWojciech ZarebaJaved ButlerArwa YounisScott McNittMary W BrownJonathan SteinbergLeway ChenJeffrey D AlexisHimabindu VidulaIlan GoldenbergPublished in: Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc (2022)
The Confirm-AF trial seeks to accurately define the burden of AF in high-risk HF patients with LVEF > 35% using an Abbott ICM. A finding showing significantly higher incidence of AF along with improved clinical outcomes with ICM monitoring is expected to have substantial clinical implications and may change the method of monitoring high-risk HF patients.
Keyphrases
- atrial fibrillation
- ejection fraction
- end stage renal disease
- catheter ablation
- oral anticoagulants
- left atrial
- left atrial appendage
- study protocol
- clinical trial
- phase iii
- heart failure
- chronic kidney disease
- direct oral anticoagulants
- risk factors
- newly diagnosed
- phase ii
- percutaneous coronary intervention
- peritoneal dialysis
- prognostic factors
- left ventricular
- randomized controlled trial
- coronary artery disease
- real time pcr
- sensitive detection
- quantum dots
- label free